Bookmark and Share
BioAssay: AID 1968

Broad Institute MLPCN T. Cruzi Inhibition Project

The main goal is to identify new drugs for the treatment of Chagas disease. New drugs are needed because the only two drugs currently available are only effective against the early stages of disease and have significant toxicity to the patient. No drug is available to treat the chronic stage. This assay approach is intended to select drugs that will be effective against the early stages of more ..
_
   
 Tested Compounds
 Tested Compounds
All(3)
 
 
Probe(3)
 
 
Active(3)
 
 
 Tested Substances
 Tested Substances
All(3)
 
 
Probe(3)
 
 
Active(3)
 
 
 Related BioAssays
 Related BioAssays
AID: 1968
Data Source: Broad Institute (2017_Inhibitors)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-10-08
Modify Date: 2011-03-10

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: Chemical Probe: 3    Active: 3
Related Experiments
Show more
AIDNameTypeComment
1885Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi ReplicationScreeningdepositor-specified cross reference: 303286 hts compounds at singlepoint in T. Cruzi Inhibition: Beta Gal reporter measuring activity
2010Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells.Confirmatorydepositor-specified cross reference: 4065 cherrypick compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1
2044Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruzi Replication.Confirmatorydepositor-specified cross reference: 4065 cherrypick compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1
2294Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi InfectionConfirmatorydepositor-specified cross reference
2396Luminescence Cell-Based/Microorganism Confirmation at Dose of Inhibitors of T.Cruzi InfectionConfirmatorydepositor-specified cross reference: 27 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 1
2586Luminescence Cell-Based Secondary HTS screen to identify cytotoxic compounds of NIH3T3 cellsConfirmatorydepositor-specified cross reference: 27 drypowder compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1
2630Luminescence Cell-Based/Microorganism Confirmation at dose of Inhibitors of T.Cruzi InfectionConfirmatorydepositor-specified cross reference: 42 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 2
2632Fluorescence Cell-Based/Microorganism Screen to Determine Compound Effect on T. cruzi in NIH3T3 CellsScreeningdepositor-specified cross reference: 42 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 2
493197Intracellular Trypanosomes Measured in Cell-Based/Microorganism System Using Plate Reader - 2017-01_Inhibitor_Dose_DryPowder_Activity_Set3Confirmatorydepositor-specified cross reference: 46 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 3
493247NIH/3T3(mouse embryonic fibroblast cell line) toxicity Measured in Cell-Based System Using Plate Reader - 2017-02_Inhibitor_Dose_DryPowder_Activity_Set2Confirmatorydepositor-specified cross reference: 46 drypowder compounds at dose in NIH3T3 toxicity: CTG measuring activity set 2
Description:
Primary Collaborators:
Ana Rodriguez, New York University, Ana.Rodriguez@nyumc.org
Esther Bettiol,Merck/Serano,estherbettiol@hotmail.com

Probes:
ML157, ML158, ML164

Biological Relevance:
The main goal is to identify new drugs for the treatment of Chagas disease. New drugs are needed because the only two drugs currently available are only effective against the early stages of disease and have significant toxicity to the patient. No drug is available to treat the chronic stage. This assay approach is intended to select drugs that will be effective against the early stages of disease when parasites are found mainly extracellularly, but also drugs that will be effective against the chronic stage, where parasites are found inside host cells. Therefore we will select drugs that are either trypanostatic (expected to be effective in the acute phase of disease) or trypanocidal (expected to be effective against the chronic stage).

Keywords: Trypanosoma cruzi, Chagas disease
Comment
The following compounds [SID] were purchased or synthesized for this project:
87219026 87219027 87219028 87219029 87219030 87219031 87219032 87219033 87219034 87219035 87219036 87219037 87219038 87219039 87219040 87219041 87219042 87219043 87219044 87219045 87219046 87219047 87219048 87219049 87219050 87219051 87219052 87556788 87556789 87556790 87556791 87556792 87556793 87556794 87556795 87556796 87556797 87556798 87556799 87556800 87556801 87556802
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1ML_NUMML number assigned to compound.String
Additional Information
Grant Number: MH085673-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: